12 completed, 1 suspended, 1 unknown. 7 Phase 3, 5 Phase 2, 2 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 6, Suspended 1 |
| Phase 2 | 5 | Completed 4, Unknown 1 |
| Not applicable | 2 | Completed 2 |
| Phase 1 | 1 | Unknown 1 |
Follow Viusid: new trials by email Literature Review of Viusid trials Research Report on Viusid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome Viusid Oral Solution, Placebo - Post-COVID-19 Syndrome, COVID-19 | Not applicable | Completed | Catalysis SL | 200 | 2022-02-15 | 2024-06-03 |
| Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip Viusid and Asbrip, COVID-19 Standard Therapy - Covid19, COVID-19 Pneumonia | Not applicable | Completed | Catalysis SL | 80 | 2021-01-08 | 2022-04-13 |
| Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19 Viusid, Asbrip, Standard Care - Covid19, Respiratory Disease | Phase 2 | Completed | Catalysis SL | 60 | 2020-11-09 | 2021-10-21 |
| Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19 Viusid and Asbrip - Covid-19, Sars-CoV2 | Phase 2 | Completed | Catalysis SL | 60 | 2020-05-04 | 2021-01-08 |
| Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal Viusid®, Glizigen®, Viusid Placebo - Papilloma Viral Infection, Papillomavirus Infections | Phase 2 | Completed | Catalysis SL | 110 | 2015-10-15 | 2019-05-22 |
| Safety and Efficacy of Oncoxin in Hepatocellular Carcinoma (HCC) Oncoxin, Supportive treatment - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Unknown | Clinical Research Organization, Dhaka, Bangladesh | 40 | 2011-07-01 | 2012-12-12 |
| Glizigen-Viudid-External Anogenital Warts in Children and Adolescents Glizigen + Viusid, Placebo - External Anogenital Warts | Phase 3 | Completed | Catalysis SL | 76 | 2010-12-01 | 2012-05-08 |
| Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson's Disease VIUSID/ALZER, Placebo - Parkinson's Disease | Phase 3 | Completed | Catalysis SL | 100 | 2009-10-01 | 2012-05-04 |
| Viusid Administration in Subjects With Chronic Inflammatory Syndrome Under Hemodialysis Treatment Viusid, Placebo - Chronic Inflammatory Syndrome | Phase 3 | Suspended | Catalysis SL | 152 | 2009-10-01 | 2010-07-07 |
| Viusid in Adults With Acute Fever of Viral Etiology Viusid, Conventional treatment - Acute Fever of Viral Etiology | Phase 2 | Completed | Catalysis SL | 200 | 2009-09-01 | 2010-05-18 |
| Efficacy of Oncoxin Plus Viusid in the Treatment of Rheumatoid Arthritis Oncoxin + Viusid, Placebo - Rheumatoid Arthritis | Phase 3 | Completed | Catalysis SL | 86 | 2009-09-01 | 2011-05-09 |
| Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C Viusid, Placebo - Chronic Hepatitis C | Phase 3 | Completed | Catalysis SL | 60 | 2008-10-01 | 2012-05-04 |
| Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis Viusid, Hypocaloric Diet with controlled exercise - Nonalcoholic Steatohepatitis | Phase 3 | Completed | Catalysis SL | 60 | 2007-02-01 | 2009-01-12 |
| Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection. Viusid (nutritional supplement), Placebo - Cirrhosis, Chronic Hepatitis C | Phase 3 | Completed | Catalysis SL | 100 | 2005-05-01 | 2011-02-11 |
COVID-19 (4) · Carcinoma, Hepatocellular (2) · Hepatitis C, Chronic (2) · Arthritis, Rheumatoid (1) · Condylomata Acuminata (1) · Coronavirus Infections (1) · Cough (1) · Diabetes Mellitus (1) · Dyspnea (1) · Fatigue (1) · Fibrosis (1) · Heart Diseases (1) · Inflammation (1) · Kidney Diseases (1) · Liver Diseases (1)
Catalysis SL (13) · Clinical Research Organization, Dhaka, Bangladesh (1)
Cuba (9) · Bangladesh (1) · Bulgaria (1) · Colombia (1) · Ecuador (1) · Kazakhstan (1)
Edelisa Moredo Romo, MD (1) · Eduardo Vilar Gomez, Ph.D (1) · Jose Luis Guiroud, PhD (1) · Juan Carlos Delgado Morales, MD (1) · Mamun A Mahtab, MSc MD FACG (1)